JP2022529036A5 - - Google Patents

Info

Publication number
JP2022529036A5
JP2022529036A5 JP2021561772A JP2021561772A JP2022529036A5 JP 2022529036 A5 JP2022529036 A5 JP 2022529036A5 JP 2021561772 A JP2021561772 A JP 2021561772A JP 2021561772 A JP2021561772 A JP 2021561772A JP 2022529036 A5 JP2022529036 A5 JP 2022529036A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable domain
antigen
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021561772A
Other languages
English (en)
Japanese (ja)
Other versions
JP7297928B2 (ja
JP2022529036A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/060579 external-priority patent/WO2020212415A1/en
Publication of JP2022529036A publication Critical patent/JP2022529036A/ja
Publication of JP2022529036A5 publication Critical patent/JP2022529036A5/ja
Priority to JP2023097183A priority Critical patent/JP7601952B2/ja
Application granted granted Critical
Publication of JP7297928B2 publication Critical patent/JP7297928B2/ja
Priority to JP2024212212A priority patent/JP7882929B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021561772A 2019-04-17 2020-04-15 二重特異性抗体 Active JP7297928B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023097183A JP7601952B2 (ja) 2019-04-17 2023-06-13 二重特異性抗体
JP2024212212A JP7882929B2 (ja) 2019-04-17 2024-12-05 二重特異性抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19169704.4 2019-04-17
EP19169704 2019-04-17
EP19213867.5 2019-12-05
EP19213867 2019-12-05
PCT/EP2020/060579 WO2020212415A1 (en) 2019-04-17 2020-04-15 Bispecific antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097183A Division JP7601952B2 (ja) 2019-04-17 2023-06-13 二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2022529036A JP2022529036A (ja) 2022-06-16
JP2022529036A5 true JP2022529036A5 (cg-RX-API-DMAC7.html) 2023-04-25
JP7297928B2 JP7297928B2 (ja) 2023-06-26

Family

ID=70189980

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021561772A Active JP7297928B2 (ja) 2019-04-17 2020-04-15 二重特異性抗体
JP2023097183A Active JP7601952B2 (ja) 2019-04-17 2023-06-13 二重特異性抗体
JP2024212212A Active JP7882929B2 (ja) 2019-04-17 2024-12-05 二重特異性抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023097183A Active JP7601952B2 (ja) 2019-04-17 2023-06-13 二重特異性抗体
JP2024212212A Active JP7882929B2 (ja) 2019-04-17 2024-12-05 二重特異性抗体

Country Status (19)

Country Link
US (3) US11325983B2 (cg-RX-API-DMAC7.html)
EP (1) EP3956359A1 (cg-RX-API-DMAC7.html)
JP (3) JP7297928B2 (cg-RX-API-DMAC7.html)
KR (2) KR102652906B1 (cg-RX-API-DMAC7.html)
CN (1) CN113692415B (cg-RX-API-DMAC7.html)
AU (1) AU2020259982B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021019959A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135632A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002710A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014072A2 (cg-RX-API-DMAC7.html)
IL (1) IL286757A (cg-RX-API-DMAC7.html)
MA (1) MA55705A (cg-RX-API-DMAC7.html)
MX (1) MX2021012365A (cg-RX-API-DMAC7.html)
MY (1) MY206180A (cg-RX-API-DMAC7.html)
PE (1) PE20212262A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552586A1 (cg-RX-API-DMAC7.html)
SA (1) SA521430592B1 (cg-RX-API-DMAC7.html)
WO (1) WO2020212415A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202107426B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212262A1 (es) * 2019-04-17 2021-11-29 Novo Nordisk As Anticuerpos biespecificos
CN116137870B (zh) 2020-10-12 2025-02-18 日本制铁株式会社 热浸镀锌钢板
JP2025506341A (ja) * 2022-02-03 2025-03-11 アイジーエム バイオサイエンシズ インコーポレイテッド 抗cd38結合分子及びその使用
CN118786148A (zh) * 2022-03-02 2024-10-15 诺和诺德医疗保健公司 每周一次施用fviii模拟双特异性抗体的方法
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
TW202546001A (zh) * 2024-02-08 2025-12-01 丹麥商赫邁博私人有限責任公司 用於治療凝血病變的方法
CN119285785B (zh) * 2024-09-26 2025-04-18 武汉奥科博泰生物科技有限公司 一种抗d-二聚体单克隆抗体及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541275B1 (en) 1988-02-03 2003-04-01 Dade Behring Inc. Immunoassay for F1.2 prothrombin fragment
TW212184B (cg-RX-API-DMAC7.html) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
JPH05168494A (ja) 1991-05-17 1993-07-02 Takeda Chem Ind Ltd ハイブリッド・モノクローナル抗体および抗体含有薬剤
EP0771216B9 (en) 1994-07-11 2003-01-02 The Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of tumoral vasculature
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
DE19802139C1 (de) 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
US20040180409A1 (en) 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
DE10354403A1 (de) 2003-11-20 2005-06-23 Dade Behring Marburg Gmbh Gegen das Prothrombin-Fragment F 1+2 gerichtete Antikörper, ihre Herstellung und Verwendung
US7393833B2 (en) 2005-03-09 2008-07-01 The Board Of Regents Of The University Of Oklahoma Chimeric proteins with phosphatidylserine binding domains
ES2353084T3 (es) 2006-04-07 2011-02-25 Novo Nordisk Health Care Ag Complejo covalente de factor vii y factor tisular.
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
US20110077202A1 (en) 2008-05-16 2011-03-31 Bayer Healthcare Llc Targeted Coagulation Factors and Method of Using the Same
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
CN102361884A (zh) * 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
WO2011023785A1 (en) 2009-08-27 2011-03-03 Novo Nordisk A/S Targeting tissue factor to activated platelets
CN103153327B (zh) 2010-04-08 2016-01-20 国家健康与医学研究院 衍生自trem样转录1(tlt-1)的抑制肽和其用途
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
CN104788557A (zh) 2010-09-15 2015-07-22 诺沃—诺迪斯克有限公司 具有减少的细胞摄取的因子viii变体
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
AU2012222366A1 (en) * 2011-03-02 2013-08-01 Novo Nordisk A/S Coagulation factor-targeting to TLT-1 on activated platelets
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
AU2018216008A1 (en) * 2017-02-01 2019-08-01 Novo Nordisk A/S Procoagulant antibodies
PE20212262A1 (es) * 2019-04-17 2021-11-29 Novo Nordisk As Anticuerpos biespecificos

Similar Documents

Publication Publication Date Title
JP2024504384A5 (cg-RX-API-DMAC7.html)
JP2022525377A5 (cg-RX-API-DMAC7.html)
JP2020508303A5 (cg-RX-API-DMAC7.html)
JP2024167313A5 (cg-RX-API-DMAC7.html)
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
FI4045533T3 (fi) Ihmisen monoklonaalisia vasta-aineita vakavalle akuutille koronavirus 2 -hengityselinoireyhtymälle (sars-cov-2)
JP2020079252A5 (cg-RX-API-DMAC7.html)
RU2009129403A (ru) Антитела, нейтрализующие цитомегаловирус человека, и их применение
JP2023515271A5 (cg-RX-API-DMAC7.html)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2017533694A5 (cg-RX-API-DMAC7.html)
JP2006512899A5 (cg-RX-API-DMAC7.html)
JP2017528476A5 (cg-RX-API-DMAC7.html)
IL261585A (en) Antigen-binding human proteins that bind beta-klotho, fgf receptors and their complexes
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
JP2021501579A5 (cg-RX-API-DMAC7.html)
JP2020500538A5 (cg-RX-API-DMAC7.html)
JP2010516229A5 (cg-RX-API-DMAC7.html)
JP2018035138A5 (cg-RX-API-DMAC7.html)
JP2018535650A5 (cg-RX-API-DMAC7.html)
JPWO2023026791A5 (cg-RX-API-DMAC7.html)
JP2015534982A5 (cg-RX-API-DMAC7.html)
JP2024109911A5 (cg-RX-API-DMAC7.html)
HRP20201503T1 (hr) MOLEKULE SA SPECIFIČNOŠĆU ZA CD45 i CD79
JP2013529183A5 (cg-RX-API-DMAC7.html)